Hyperbaric ozone autohemotherapy in Barrett’s Esophagus associated with Helicobacter pylori infection: a comparative, controlled, longitudinal clinical study
DOI:
https://doi.org/10.52673/18570461.25.4-79.06Keywords:
Barrett’s esophagus, Helicobacter pylori, ozone autohemotherapy, oxidative stressAbstract
Barrett’s Esophagus (BE) is a precancerous esophageal condition often associated with chronic gastroesophageal reflux, while the role of Helicobacter pylori (H. pylori) infection in its progression remains controversial. Oxidative stress and chronic inflammation are key factors in the advancement of esophageal metaplasia. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) emerges as a promising adjuvant therapeutic option due to its antioxidant and immunomodulatory effects. This study included 60 patients with BE and active H. pylori infection, randomized into two equal groups: one treated with standard therapy combined with AHT-O₃, and one receiving standard therapy alone. Over a 12-month period, clinical, endoscopic, histological, and paraclinical evaluations were performed, including markers of oxidative stress, immunophenotyping, H. pylori infection status, CRP levels, GIQLI scores, and the dynamics of esophageal lesions. Ozone therapy led to a significant reduction in the oxidative stress marker malondialdehyde (MDA) and a notable increase in antioxidant enzymes (SOD, GPx, GST), indicating a restoration of redox balance. Concurrently, a significant increase in T-helper cells and a decrease in inflammatory T cells were observed, reflecting a favorable immune response. Parameters specific to H. pylori infection (IgA, IgG, fecal antigen) showed a more pronounced reduction in the ozone treatment group, indicating superior eradication efficiency. CRP levels decreased significantly, and GIQLI scores revealed a marked improvement in the quality of life. Endoscopic and histological assessments demonstrated a significantly higher rate of complete or partial regression of Barrett’s lesions in the ozone-treated group. Hyperbaric ozone autohemotherapy, when integrated into the standard therapeutic regimen, proved effective in counteracting oxidative stress, modulating immune responses, and significantly improving the clinical and histological status of patients with BE and H. pylori infection. These results support the use of this method as a complementary therapeutic strategy with added value in gastroenterology.
References
1. Shaoze, S.; Guo, X. ; Wang, C.; Yin, Y.; Xu, G.; Chen, H., & Qi, X. Association of Barrett’s esophagus with He-licobacter pylori infection: a meta-analysis. Therapeu-tic Advances in Chronic Disease, 2022, 13, https://doi.org/10.1177/20406223221117971
2. Wang, Z.; Shaheen, N.; Whiteman, D.; Anderson, L.; Vaughan, T.; Corley, D.; El‐Serag, H.; Rubenstein, J., & Thrift, A. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett’s Esophagus: An Analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium, în: American Journal of Gastroenterology, 2018, 113, 1148-1155, https://doi.org/10.1038/s41395-018-0070-3
3. Rubenstein, J.; Inadomi, J.; Scheiman, J.; Schoenfeld, P.; Appelman, H.; Zhang, M.; Metko, V., & Kao, J. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clinical gastroenterology and hepatology: the official cli-nical practice journal of the American Gastroenterological Association, 2014, 12, 2, 239-245, https://doi.org/10.1016/j.cgh.2013.08.029
4. Fischbach, L.; Graham, D.; Kramer, J.; Rugge, M.; Verstovsek, G.; Parente, P.; Alsarraj, A.; Fitzgerald, S.; Shaib, Y.; Abraham, N.; Kolpachi, A.; Gupta, S.; Vela, M.; Vélez, M.; Cole, R.; Anand, B. & Serag, H. Association between He-licobacter pylori and Barrett’s Esophagus: A Case–Control Study, în: American Journal of Gastroenterology, 2014, 109, 357-368, https://doi.org/10.1038/ajg.2013.443
5. Erőss, B.; Farkas, N; Vincze, Á.; Tinusz, B; Szapáry, L.; Garami, A.; Balaskó, M.; Sarlós, P; Czopf, L; Alizadeh, H; Rakonczay, Z; Habon, T. & Hegyi, P. Helicobacter pylori infection reduces the risk of Barrett’s esophagus: A meta‐ analysis and systematic review, în: Helicobacter, 2018, 23, https://doi.org/10.1111/hel.12504
6. Du, Y.; Duan, R. & Duan, L. Helicobacter pylori infec-tion is associated with reduced risk of Barrett’s esophagus: a meta-analysis and systematic review. BMC Gastroentero-logy, 2021, 21, https://doi.org/10.1186/s12876-021-02036-5
7. Corley, D.; Kubo, A.; Levin, T.; Block, G.; Habel, L.; Zhao, W.; Leighton, P.; Rumore, G.; Quesenberry, C.; Buffler, P. & Parsonnet, J. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut, 2007, 57, 727-733, https://doi.org/10.1136/gut.2007.132068
8. Thrift, A.; Pandeya, N.; Smith, K.; Green, A.; Hayward, N.; Webb, P.; & Whiteman, D. Helicobacter pylori infection and the risks of Barrett’s oesophagus: A popula-tion‐based case–control study, în: International Journal of Cancer, 2012, 130, https://doi.org/10.1002/ijc.26242
9. Mitsuyama, R.; Cao, W. & Hyder, S. S2389 The Odd Couple: Active H. pylori Infection Within Long Segment Barrett’s Esophagus, în: American Journal of Gastroenterology, 2022, https://doi.org/10.14309/01.ajg.0000866196.43440.af
10. Aghayeva, S.; Mara, K. & Katzka, D. The impact of Helicobacter pylori on the presence of Barrett’s esophagus in Azerbaijan, a high-prevalence area of infection. Disea-ses of the esophagus: official journal of the International Society for Diseases of the Esophagus, 2019, https://doi.org/10.1093/dote/doz053
11. Doorakkers, E.; Lagergren, J.; Santoni, G.; En-gstrand, L. & Brusselaers, N. Helicobacter pylori eradication treatment and the risk of Barrett’s esophagus and esophage-al adenocarcinoma, în: Helicobacter, 2020, 25, https://doi.org/10.1111/hel.12688
12. Kauppi, J.; Räsänen, J.; Sihvo, E.; Nieminen, U.; Ark-kila, P.; Ahotupa, M.; & Salo, J. Increased Oxidative Stress in the Proximal Stomach of Patients with Barrett’s Esophagus and Adenocarcinoma of the Esophagus and Esophagogas-tric Junction1. Translational Oncology, 2016, 9, 336-339, https://doi.org/10.1016/j.tranon.2016.06.004
13. Han, D.; & Zhang, C. The Oxidative Damage and Inflammation Mechanisms in GERD-Induced Barrett’s Esophagus. Frontiers in Cell and Developmental Biology, 2022, 10, https://doi.org/10.3389/fcell.2022.885537
14. O’ Farrell, N.; Phelan, J.; Feighery, R.; Doyle, B.; Pi-cardo, S.; Ravi, N.; O’Toole, D.; Reynolds, J. & O’Sullivan, J. Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrett’s Esophagus Compared to Esophageal Adenocarcinoma, în: International Journal of Molecular Sciences, 2019, 20, https://doi.org/10.3390/ijms20184449
15. Pradeep, M.; Joshi, D.; Bernard, J.; Andl, T. & Andl, C. Abstract 2204: Probiotic Lactobacilli and their secreted metabolites exert anti-inflammatory and anti-genotoxic effects in Barrett’s esophagus associated tumorigenesis in vitro and in vivo, în: Cancer Research, 2025, https://doi.org/10.1158/1538-7445.am2025-2204
16. Murata, M. Inflammation and cancer. Environmen-tal Health and Preventive Medicine, 2018, 23, https://doi.org/10.1186/s12199-018-0740-1
17. Kumar, S. & Dhiman, M. Helicobacter pylori se-cretary Proteins-Induced oxidative stress and its role in NLRP3 inflammasome activation, în: Cellular immuno-logy, 2024, 399-400, 104811, https://doi.org/10.1016/j.ce-llimm.2024.104811
18. Naito, Y. & Yoshikawa, T. Molecular and cellular mechanisms involved in Helicobacter pylori-induced in-flammation and oxidative stress. Free radical biology & me-dicine, 2002, 33 3, 323-36, https://doi.org/10.1016/S0891-5849(02)00868-7
19. Hardbower, D.; De Sablet, T.; Chaturvedi, R.; & Wilson, K. Chronic inflammation and oxidative stress, în: Gut Microbes, 4, 2013, 475-481, https://doi.org/10.4161/gmic.25583
20. Dvorak, K.; Payne, C.; Chavarria, M.; Ramsey, L.; Dvořáková, B.; Bernstein, H.; Holubec, H.; Sampliner, R.; Guy, N.; Condon, A.; Bernstein, C.; Green, S.; Prasad, A. & Garewal, H. Bile acids in combination with low pH in-duce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett’s oesophagus. Gut, 2006, 56, 763- 771, https://doi.org/10.1136/gut.2006.103697
21. Bocci, V. Ozone: A New Medical Drug. Springer. 2011.
22. Bocci, V.; Zanardi, I.; & Travagli, V. Oxygen-ozo-ne therapy: A critical evaluation. Evidence-Based Comple-mentary and Alternative Medicine. 2011, 6(3), 295-310, https://doi.org/10.1186/2045-9912-1-6
23. Botezatu, A.; Re, L.; Yeprem, L.; & Bodrug. N. (2025). The Utility of Medical Ozone as Integrative Tool in The Treatment of Gastric Cancer: Review Article, în: Ame-rican Journal of Medical and Clinical Research & Reviews, 2009, 4(5), 1-11, https://doi.org/10.58372/2835-6276.1294
24. Re, L.; Martínez-Sánchez, G. & Bordicchia, M. Ozone therapy: Clinical and basic evidence of its therapeu-tic potential, în: Archives of Medical Research, 2014, 45(7), 593-600.
25. Viebahn-Haensler, R.; & Fernández, O. Ozone in Medicine. The Low-Dose Ozone Concept and Its Basic Bi-ochemical Mechanisms of Action in Chronic Inflammatory Diseases, în: International Journal of Molecular Sciences, 2021, 22, https://doi.org/10.3390/ijms22157890
26. Delgado-Roche, L.; Riera-Romo, M; Mesta, F; Her-nández-Matos, Y; Barrios, J; Martínez-Sánchez, G; & Al-Da-laien, S. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients, în: European journal of phar-macology, 2017, 811, 148-154, https://doi.org/10.1016/j.ejphar.2017.06.017
27. Clavo, B.; Martínez-Sánchez, G.; Rodríguez-Es-parragón, F.; Rodríguez-Abreu, D.; Galván, S.; Aguiar-Bu-janda, D.; Díaz-Garrido, J.; Cañas, S.; Torres-Mata, L.; Fabe-lo, H.; Téllez, T.; Santana-Rodríguez, N.; Fernández-Pérez, L.; & Marrero-Callico, G. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Ne-uropathy: The Background for a Randomized Clinical Trial, în: International Journal of Molecular Sciences, 2021, 22, https://doi.org/10.3390/ijms22062802
28. Pelinsari, S.; Sarandy, M.; Vilela, E.; Novaes, R.; Sc-hlamb, J.; & Gonçalves, R. Ozone Exposure Controls Oxi-dative Stress and the Inflammatory Process of Hepatocytes in Murine Models, în: Antioxidants, 2024, 13, https://doi.org/10.3390/antiox13020212
29. Sagai, M.; & Bocci, V. Mechanisms of Action Invol-ved in Ozone Therapy: Is healing induced via a mild oxida-tive stress? în: Medical Gas Research, 2011, 1, 29-29, https://doi.org/10.1186/2045-9912-1-29
30. Pelinsari, S. How the ozone therapy can influen-ce the redox metabolism and the inflammatory process of hepatocytes in murine models? A systematic review, 2023, https://doi.org/10.47328/ufvbbt.2022.495
31. Rapone, B.; Ferrara, E.; Qorri, E.; Inchingolo, F.; Isola, G.; Dongiovanni, P.; Tartaglia, G.; & Scarano, A. Research efficacy of gaseous ozone therapy as an adjuvant to periodontal treatment on oxidative stress mediators in pati-ents with type 2 diabetes: a randomized clinical trial. BMC Oral Health, 2023, 23, https://doi.org/10.1186/s12903-023-02985-1
32. Delgadillo-Valero, L.; Hernández-Cruz, E.; & Pe-draza-Chaverri, J. The Protective Role of Ozone Therapy in Kidney Disease: A Review. Life, 2023, 13, https://doi.org/10.3390/life13030752
33. Hashigami, K.; Iwaya, Y.; Nagaya, T.; Hara, D.; Hi-rayama, A.; Okamura, T.; Akamatsu, T.; & Umemura, T. Relationship between Helicobacter pylori Eradication and Barrett’s Esophagus Elongation. Digestion, 2024, 105, 186-191, https://doi.org/10.1159/000536443
34. De Sire, A.; Marotta, N.; Ferrillo, M.; Agostini, F.; Sconza, C.; Lippi, L.; Respizzi, S.; Giudice, A.; Invernizzi, M.; & Ammendolia, A. (2022). Oxygen-Ozone Therapy for Reducing Pro-Inflammatory Cytokines Serum Leve-ls in Musculoskeletal and Temporomandibular Disorders: A Comprehensive Review, în: International Journal of Mo-lecular Sciences, 23, https://doi.org/10.3390/ijms23052528
